CNS drug design: balancing physicochemical properties for optimal brain exposure.
暂无分享,去创建一个
[1] J J Baldwin,et al. Prediction of drug absorption using multivariate statistics. , 2000, Journal of medicinal chemistry.
[2] James S. Scott,et al. Optimization of brain penetrant 11β-hydroxysteroid dehydrogenase type I inhibitors and in vivo testing in diet-induced obese mice. , 2014, Journal of medicinal chemistry.
[3] G. Pasternak,et al. Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. , 1989, The Journal of pharmacology and experimental therapeutics.
[4] Paul W Smith,et al. The discovery of a series of N-substituted 3-(4-piperidinyl)-1,3-benzoxazolinones and oxindoles as highly brain penetrant, selective muscarinic M1 agonists. , 2010, Bioorganic & medicinal chemistry letters.
[5] Xingrong Liu,et al. Rational use of plasma protein and tissue binding data in drug design. , 2014, Journal of medicinal chemistry.
[6] P. Jeffrey,et al. Challenges for blood–brain barrier (BBB) screening , 2007, Xenobiotica; the fate of foreign compounds in biological systems.
[7] H. Pajouhesh,et al. Medicinal chemical properties of successful central nervous system drugs , 2005, NeuroRX.
[8] M. Shalaeva,et al. High throughput method for the indirect detection of intramolecular hydrogen bonding. , 2014, Journal of medicinal chemistry.
[9] Maxime Culot,et al. Modelling of the blood–brain barrier in drug discovery and development , 2007, Nature Reviews Drug Discovery.
[10] Wei Liu,et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain expos , 2014, Journal of medicinal chemistry.
[11] M. Wigglesworth,et al. Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders. , 2010, Journal of medicinal chemistry.
[12] Thomas J. Raub,et al. In vitro models of the blood-brain barrier. , 1998, Alternatives to laboratory animals : ATLA.
[13] Anders Tunek,et al. High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. , 2007, Journal of medicinal chemistry.
[14] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[15] Xingrong Liu,et al. Strategies to optimize brain penetration in drug discovery. , 2005, Current opinion in drug discovery & development.
[16] U. Norinder,et al. Computational approaches to the prediction of the blood-brain distribution. , 2002, Advanced drug delivery reviews.
[17] Edward H. Kerns,et al. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery , 2010, Nature Reviews Drug Discovery.
[18] Eyassu Chernet,et al. Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples. , 2005, Life sciences.
[19] R. Béliveau,et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep‐2 , 2008, British journal of pharmacology.
[20] Stephen A. Wring,et al. Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs , 2002, Journal of Pharmacology and Experimental Therapeutics.
[21] P. Roepe,et al. The P-Glycoprotein Efflux Pump: How Does it Transport Drugs? , 1998, The Journal of Membrane Biology.
[22] Thomas J. Raub,et al. Breast Cancer Resistance Protein Interacts with Various Compounds in Vitro, but Plays a Minor Role in Substrate Efflux at the Blood-Brain Barrier , 2009, Drug Metabolism and Disposition.
[23] P. Borst,et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[24] Yuan Cheng,et al. Design and preparation of a potent series of hydroxyethylamine containing β-secretase inhibitors that demonstrate robust reduction of central β-amyloid. , 2012, Journal of medicinal chemistry.
[25] Kelly H. Jordan,et al. Steady-State Brain Concentrations of Antihistamines in Rats , 2004, Pharmacology.
[26] Arup K. Ghose,et al. Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery , 2011, ACS chemical neuroscience.
[27] F. Berardi,et al. Trimethoxybenzanilide-based P-glycoprotein modulators: an interesting case of lipophilicity tuning by intramolecular hydrogen bonding. , 2014, Journal of medicinal chemistry.
[28] T. Davis,et al. The Blood-Brain Barrier/Neurovascular Unit in Health and Disease , 2005, Pharmacological Reviews.
[29] P. Verhoest,et al. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010, ACS chemical neuroscience.
[30] A. Leo,et al. Partition coefficients and their uses , 1971 .
[31] A. Marxer,et al. Hypotensive hydrazinophthalazines and related compounds. , 1959, Journal of medicinal and pharmaceutical chemistry.
[32] Jos H Beijnen,et al. Brain accumulation of sunitinib is restricted by P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration , 2012, International journal of cancer.
[33] S. Hitchcock,et al. Structure-brain exposure relationships. , 2006, Journal of medicinal chemistry.
[34] M. Gleeson. Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.
[35] J R Chretien,et al. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. , 1998, Journal of drug targeting.
[36] M. Yliperttula,et al. Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[37] P. Patsalos,et al. The pharmacokinetic inter-relationship of tiagabine in blood, cerebrospinal fluid and brain extracellular fluid (frontal cortex and hippocampus) , 2004, Seizure.
[38] T. Richmond,et al. Solvent accessible surface area and excluded volume in proteins. Analytical equations for overlapping spheres and implications for the hydrophobic effect. , 1984, Journal of molecular biology.
[39] Mark Muzi,et al. Verapamil P-glycoprotein Transport across the Rat Blood-Brain Barrier: Cyclosporine, a Concentration Inhibition Analysis, and Comparison with Human Data , 2006, Journal of Pharmacology and Experimental Therapeutics.
[40] Geri A. Sawada,et al. Early Preclinical Evaluation of Brain Exposure in Support of Hit Identification and Lead Optimization , 2006 .
[41] Sara Eyal,et al. Drug interactions at the blood-brain barrier: fact or fantasy? , 2009, Pharmacology & therapeutics.
[42] A. Reichel. Addressing Central Nervous System (CNS) Penetration in Drug Discovery: Basics and Implications of the Evolving New Concept , 2009, Chemistry & biodiversity.
[43] Susanne Winiwarter,et al. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. , 2009, Journal of medicinal chemistry.
[44] K. Bui,et al. Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate. , 2010, Bioorganic & medicinal chemistry letters.
[45] L. Hennig,et al. Fluorine hydrogen short contacts and hydrogen bonds in substituted benzamides , 2009 .
[46] Kelly H. Jordan,et al. P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine. , 2003, Journal of pharmaceutical sciences.
[47] B. Långström,et al. Species Differences in Blood-Brain Barrier Transport of Three Positron Emission Tomography Radioligands with Emphasis on P-Glycoprotein Transport , 2009, Drug Metabolism and Disposition.
[48] Remigijus Didziapetris,et al. Classification Analysis of P-Glycoprotein Substrate Specificity , 2003, Journal of drug targeting.
[49] Richard Morphy,et al. The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds. , 2006, Journal of medicinal chemistry.
[50] K Gubernator,et al. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. , 1998, Journal of medicinal chemistry.
[51] Victor A. Levin,et al. RELATIONSHIP OF OCTANOL/WATER PARTITION COEFFICIENT AND MOLECULAR WEIGHT TO RAT BRAIN CAPILLARY PERMEABILITY , 1980 .
[52] J. Macor,et al. Discovery of a novel series of quinolone α7 nicotinic acetylcholine receptor agonists. , 2013, Bioorganic & medicinal chemistry letters.
[53] J. Dobbing,et al. THE BLOOD-BRAIN BARRIER , 1961, The Lancet.
[54] W. Pardridge. The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.
[55] M. Monshouwer,et al. Unbound Drug Concentration in Brain Homogenate and Cerebral Spinal Fluid at Steady State as a Surrogate for Unbound Concentration in Brain Interstitial Fluid , 2009, Drug Metabolism and Disposition.
[56] A. Brown,et al. Effects of terfenadine and its metabolites on a delayed rectifier K+ channel cloned from human heart. , 1993, Molecular pharmacology.
[57] S-M Huang,et al. Why Clinical Modulation of Efflux Transport at the Human Blood–Brain Barrier Is Unlikely: The ITC Evidence‐Based Position , 2013, Clinical pharmacology and therapeutics.
[58] B. Walther,et al. Development of a physiologically based pharmacokinetic model for the rat central nervous system and determination of an in vitro-in vivo scaling methodology for the blood-brain barrier permeability of two transporter substrates, morphine and oxycodone. , 2012, Journal of pharmaceutical sciences.
[59] C. Humblet,et al. Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.
[60] Z. Rankovic,et al. Medicinal chemistry of hERG optimizations: Highlights and hang-ups. , 2006, Journal of medicinal chemistry.
[61] R Griffiths,et al. Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists. , 1988, Journal of medicinal chemistry.
[62] Giulia Caron,et al. Integrating intramolecular hydrogen bonding (IMHB) considerations in drug discovery using ΔlogP as a tool. , 2013, Journal of medicinal chemistry.
[63] S. Hitchcock,et al. Structural modifications that alter the P-glycoprotein efflux properties of compounds. , 2012, Journal of medicinal chemistry.
[64] E. D. De Lange. Utility of CSF in translational neuroscience , 2013, Journal of Pharmacokinetics and Pharmacodynamics.
[65] M. Niemi,et al. Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.
[66] J. Pandit,et al. Discovery of Brain-Penetrant, Irreversible Kynurenine Aminotransferase II Inhibitors for Schizophrenia. , 2012, ACS medicinal chemistry letters.
[67] Richard Svensson,et al. Impact of Stereospecific Intramolecular Hydrogen Bonding on Cell Permeability and Physicochemical Properties , 2014, Journal of medicinal chemistry.
[68] Ian A. Watson,et al. Characteristic physical properties and structural fragments of marketed oral drugs. , 2004, Journal of medicinal chemistry.
[69] T. Tsuruo,et al. The 4F2hc/LAT1 complex transports l-DOPA across the blood–brain barrier , 2000, Brain Research.
[70] Markus Piel,et al. Positron emission tomography in CNS drug discovery and drug monitoring. , 2014, Journal of medicinal chemistry.
[71] J. Scherrmann,et al. Elevated concentrations of morphine 6‐beta‐D‐glucuronide in brain extracellular fluid despite low blood–brain barrier permeability , 1999, British journal of pharmacology.
[72] Paul D Leeson,et al. Time-related differences in the physical property profiles of oral drugs. , 2004, Journal of medicinal chemistry.
[73] P. Jeffrey,et al. Development of a P-glycoprotein knockout model in rodents to define species differences in its functional effect at the blood-brain barrier. , 2006, Journal of pharmaceutical sciences.
[74] M. Danhof,et al. Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting. , 2011, Journal of pharmaceutical sciences.
[75] T. Terasaki,et al. Diphenhydramine active uptake at the blood-brain barrier and its interaction with oxycodone in vitro and in vivo. , 2011, Journal of pharmaceutical sciences.
[76] György M. Keserü,et al. The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.
[77] T. Maurer,et al. RELATIONSHIP BETWEEN EXPOSURE AND NONSPECIFIC BINDING OF THIRTY-THREE CENTRAL NERVOUS SYSTEM DRUGS IN MICE , 2005, Drug Metabolism and Disposition.
[78] S. McCleary,et al. Utilization of an intramolecular hydrogen bond to increase the CNS penetration of an NK(1) receptor antagonist. , 2001, Journal of medicinal chemistry.
[79] S. Kobayashi,et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] Michael H. Abraham,et al. Scales of solute hydrogen-bonding: their construction and application to physicochemical and biochemical processes , 2010 .
[81] L. Di,et al. Demystifying brain penetration in central nervous system drug discovery. Miniperspective. , 2013, Journal of medicinal chemistry.
[82] Paul W Smith,et al. New quinoline NK3 receptor antagonists with CNS activity. , 2009, Bioorganic & medicinal chemistry letters.
[83] Ernesto Callegari,et al. Use of a Physiologically Based Pharmacokinetic Model to Study the Time to Reach Brain Equilibrium: An Experimental Analysis of the Role of Blood-Brain Barrier Permeability, Plasma Protein Binding, and Brain Tissue Binding , 2005, Journal of Pharmacology and Experimental Therapeutics.
[84] Gary M Pollack,et al. Fexofenadine Brain Exposure and the Influence of Blood-Brain Barrier P-Glycoprotein After Fexofenadine and Terfenadine Administration , 2009, Drug Metabolism and Disposition.
[85] U. Bredberg,et al. In Vitro Methods for Estimating Unbound Drug Concentrations in the Brain Interstitial and Intracellular Fluids , 2007, Drug Metabolism and Disposition.
[86] Tanja Eisenblätter,et al. A new multidrug resistance protein at the blood-brain barrier. , 2002, Biochemical and biophysical research communications.
[87] E. Hu,et al. Design, optimization, and biological evaluation of novel keto-benzimidazoles as potent and selective inhibitors of phosphodiesterase 10A (PDE10A). , 2013, Journal of medicinal chemistry.
[88] Christel A. S. Bergström,et al. Absorption classification of oral drugs based on molecular surface properties. , 2003, Journal of medicinal chemistry.
[89] K. Luthman,et al. Correlation of drug absorption with molecular surface properties. , 1996, Journal of pharmaceutical sciences.
[90] L. Doyle,et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[91] Reversible Michael additions: covalent inhibitors and prodrugs. , 2012, Mini reviews in medicinal chemistry.
[92] U. Bickel,et al. Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[93] R. Daneman,et al. The blood-brain barrier. , 2015, Cold Spring Harbor perspectives in biology.
[94] Stina Syvänen,et al. On The Rate and Extent of Drug Delivery to the Brain , 2007, Pharmaceutical Research.
[95] Iain Martin,et al. Prediction of blood-brain barrier penetration: are we missing the point? , 2004, Drug discovery today.
[96] François Bouzom,et al. Physiologically Based Pharmacokinetic Modelling of Drug Penetration Across the Blood–Brain Barrier—Towards a Mechanistic IVIVE-Based Approach , 2013, The AAPS Journal.
[97] Denis M. Bayada,et al. Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs , 1999, Pharmaceutical Research.
[98] D. Debruyne. Clinical Pharmacokinetics of Fluconazole in Superficial and Systemic Mycoses , 1997, Clinical pharmacokinetics.
[99] M. Kansy,et al. Hydrogen-Bonding Capacity and Brain Penetration , 1992, Chimia (Basel).
[100] Ian A. Watson,et al. Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux. , 2013, Molecular pharmaceutics.
[101] Q. Smith. Carrier-Mediated Drug Transport at the Blood-Brain Barrier and the Potential for Drug Targeting to the Brain , 1995 .
[102] A. Gilbert,et al. Targeted Covalent Enzyme Inhibitors , 2012 .
[103] J. Hughes,et al. Physiochemical drug properties associated with in vivo toxicological outcomes. , 2008, Bioorganic & medicinal chemistry letters.
[104] J. McKinzie,et al. In vivo rat brain opioid receptor binding of LY255582 assessed with a novel method using LC/MS/MS and the administration of three tracers simultaneously. , 2007, Life sciences.
[105] P. Leeson,et al. The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.
[106] Stephen R. Johnson,et al. Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.
[107] É. Marsault,et al. Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery. , 2011, Journal of medicinal chemistry.
[108] D. Scott,et al. Species Independence in Brain Tissue Binding Using Brain Homogenates , 2011, Drug Metabolism and Disposition.
[109] P. Selzer,et al. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.
[110] V. Tantishaiyakul,et al. Prediction of Caco-2 cell permeability using partial least squares multivariate analysis. , 2001, Die Pharmazie.
[111] Nathan Brown,et al. Multi-objective optimization methods in drug design. , 2013, Drug discovery today. Technologies.
[112] A. Kulkarni,et al. A proposed screening paradigm for discovery of covalent inhibitor drugs. , 2014, Drug metabolism letters.
[113] J. Uetrecht,et al. New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. , 1999, Chemical research in toxicology.
[114] Nathaniel G. Martin,et al. Identification, optimization, and pharmacology of acylurea GHS-R1a inverse agonists. , 2014, Journal of medicinal chemistry.
[115] R N Gunn,et al. Toward an improved prediction of human in vivo brain penetration , 2008, Xenobiotica; the fate of foreign compounds in biological systems.
[116] Xi Chen,et al. THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL , 2005, Drug Metabolism and Disposition.
[117] M. Bock,et al. Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists. , 2007, Journal of medicinal chemistry.
[118] Shobha N. Bhattachar,et al. Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. , 2011, ACS medicinal chemistry letters.
[119] E. Jonsson,et al. Stereoselective pharmacokinetics of cetirizine in the guinea pig: role of protein binding , 2006, Biopharmaceutics & drug disposition.
[120] W. Pardridge,et al. Blood-brain barrier delivery. , 2007, Drug discovery today.
[121] Huichun Zhu,et al. Discovery of (10R)-7-Amino-12-Fluoro-2,10,16-Trimethyl-15-Oxo-10,15,16,17-Tetrahydro-2H-8,4-(Metheno)Pyrazolo[4,3-H][2,5,11]Benzoxadiazacyclotetradecine-3-Carbonitrile (Pf-06463922), a Macrocyclic Inhibitor of Alk/Ros1 with Pre-Clinical Brain Exposure and Broad Spectrum Potency Against Alk-Resistant , 2014 .
[122] M. Melamed,et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[123] V A Levin,et al. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. , 1980, Journal of medicinal chemistry.
[124] Shankar Venkatraman,et al. Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease. , 2013, Journal of medicinal chemistry.
[125] Yue Weng,et al. Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding , 2009, Science.
[126] Bo Feng,et al. In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous System , 2008, Drug Metabolism and Disposition.
[127] A. Lercher. Macrocyclic BACE-1 Inhibitors Acutely Reduce Aβ in Brain After Po Application. , 2010 .
[128] Y. Martin,et al. A bioavailability score. , 2005, Journal of medicinal chemistry.
[129] E. Hansson,et al. Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.
[130] B. Kuhn,et al. Intramolecular hydrogen bonding in medicinal chemistry. , 2010, Journal of medicinal chemistry.
[131] Jill S Barnholtz-Sloan,et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[132] P. Verhoest,et al. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. , 2010, ACS chemical neuroscience.
[133] Z. Rankovic,et al. Designing CNS Drugs for Optimal Brain Exposure , 2015 .
[134] C. Hansch,et al. The parabolic dependence of drug action upon lipophilic character as revealed by a study of hypnotics. , 1968, Journal of medicinal chemistry.
[135] E. Giralt,et al. Shuttle-mediated drug delivery to the brain. , 2011, Angewandte Chemie.
[136] M. Lindstrom,et al. Discovery of a novel melanin concentrating hormone receptor 1 (MCHR1) antagonist with reduced hERG inhibition. , 2012, Bioorganic & medicinal chemistry letters.
[137] Thomas J. Raub,et al. How hydrogen bonds impact P-glycoprotein transport and permeability. , 2012, Bioorganic & medicinal chemistry letters.
[138] Stephen D Pickett,et al. The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types. , 2011, Drug discovery today.
[139] Akos Tarcsay,et al. Impact of lipophilic efficiency on compound quality. , 2012, Journal of medicinal chemistry.
[140] Jie Shen,et al. Estimation of ADME Properties with Substructure Pattern Recognition , 2010, J. Chem. Inf. Model..
[141] Daniel J. Chandler. Something's got to give: psychiatric disease on the rise and novel drug development on the decline. , 2013, Drug discovery today.
[142] Danny D Shen,et al. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. , 2004, Advanced drug delivery reviews.
[143] G. Ecker,et al. Evidence-based approach to assess passive diffusion and carrier-mediated drug transport. , 2012, Drug discovery today.
[144] N. Shaik,et al. P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib , 2009, Journal of Pharmacology and Experimental Therapeutics.
[145] Matthew P. Jacobson,et al. Predicting and improving the membrane permeability of peptidic small molecules. , 2012, Journal of medicinal chemistry.
[146] M. Waring. Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability. , 2009, Bioorganic & medicinal chemistry letters.
[147] A. Jemal,et al. Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[148] Yuichi Sugiyama,et al. Quantitative Evaluation of the Impact of Active Efflux by P-Glycoprotein and Breast Cancer Resistance Protein at the Blood-Brain Barrier on the Predictability of the Unbound Concentrations of Drugs in the Brain Using Cerebrospinal Fluid Concentration as a Surrogate , 2011, Journal of Pharmacology and Experimental Therapeutics.
[149] Alexander Alex,et al. Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space , 2011 .
[150] M. Lohse,et al. Distinct pharmacological properties of morphine metabolites at G(i)-protein and β-arrestin signaling pathways activated by the human μ-opioid receptor. , 2011, Biochemical pharmacology.
[151] Zoran Rankovic,et al. CHAPTER 18:Medicinal Chemistry Challenges in CNS Drug Discovery , 2012 .
[152] R. Béliveau,et al. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. , 2002, Vascular pharmacology.
[153] M. Potashman,et al. Covalent modifiers: an orthogonal approach to drug design. , 2009, Journal of medicinal chemistry.
[154] Paul W Smith,et al. Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator. , 2010, Journal of medicinal chemistry.
[155] M. Staufenbiel,et al. Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. , 2010, Bioorganic & medicinal chemistry letters.
[156] Osamu Okazaki,et al. A Zone Classification System for Risk Assessment of Idiosyncratic Drug Toxicity Using Daily Dose and Covalent Binding , 2009, Drug Metabolism and Disposition.
[157] M. Seelbach,et al. Peripheral inflammatory hyperalgesia modulates morphine delivery to the brain: a role for P‐glycoprotein , 2007, Journal of neurochemistry.
[158] N. J. Baxter,et al. Temperature dependence of 1H chemical shifts in proteins , 1997, Journal of biomolecular NMR.
[159] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[160] Thomas M Frimurer,et al. Melanin concentrating hormone receptor 1 (MCHR1) antagonists-Still a viable approach for obesity treatment? , 2012, Bioorganic & medicinal chemistry letters.
[161] T. Terasaki,et al. Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) on Pharmacokinetics and Central Nervous System Penetration of Abacavir and Zidovudine in the Mouse , 2008, Drug Metabolism and Disposition.